Home / Companies / News / Covid-19 impact: Hydroxychloroquine's share in pharma exports minuscule

Covid-19 impact: Hydroxychloroquine's share in pharma exports minuscule

Manufacturers say there is enough stock for local needs

Hydroxychloroquine, coronavirus, covid-19, drug, drugs, pharma, pharmaceutical

Premium

Some health researchers have used hydroxychloroquine, along with a combination of a common antibiotic azithromycin, as a potential treatment for Covid-19.

Sohini Das Mumbai

3 min read Last Updated : Apr 09 2020 | 7:25 AM IST

India, the world’s largest producer of hydroxychloroquine (HCQ), exported $51 million worth of the drug in FY19. This was a minuscule portion of the country’s $19-billion pharma exports.

In FY20, however, exports had dipped to $36 million till February. With US President Donald Trump campaigning for HCQ, global demand for the inexpensive drug has surged all of a sudden. Countries like Brazil and India’s SAARC neighbours have sought the drug from India.

The Centre itself has requisitioned 100 million tablets from Ipca Laboratories and Cadila Healthcare. Manufacturers claim there is enough stock for the Indian market, and that the surplus

Topics : Coronavirus drug export Indian Pharmaceuticals Industry Hydroxychloroquine

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in